Melatonin Receptor Agonist Agomelatine: A New Drug for Treating Unipolar Depression

Author(s): Michel Bourin, Corina Prica

Journal Name: Current Pharmaceutical Design

Volume 15 , Issue 14 , 2009

Become EABM
Become Reviewer
Call for Editor


Agomelatine markedly differs from other classes of antidepressant drugs: its primary molecular targets in vivo are the melatonin MT1 and MT2 receptors, where it acts as a potent agonist, and the 5-HT2C receptors, where it exerts clear-cut antagonist properties. Agomelatine across a wide range of clinical trials suggests that agomelatine offers an important alternative for the treatment of depression, combining efficacy, even in the most severely depressed patients, with a favorable side-effect profile. It will be of interest to see if agomelatine expands the spectrum of treatment for unipolar depression. It shows efficacy in acute phase and in of maintenance treatment compared to reference antidepressants as paroxetine and venlafaxine.

Keywords: Agomelatine, duloxetine, unipolar depression

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Published on: 01 March, 2012
Page: [1675 - 1682]
Pages: 8
DOI: 10.2174/138161209788168056
Price: $65

Article Metrics

PDF: 7